Atea Pharma reports preliminary cash balance

What financial information does Atea Pharmaceuticals (AVIR) provide in the related press release?

Rhea-AI Filing Summary

FAQ

8-K Event Classification

What did Atea Pharmaceuticals (AVIR) disclose in this 8-K filing?

Is the preliminary cash and investment information for Atea Pharmaceuticals audited?

Are Atea Pharmaceuticals’ fourth-quarter and full-year 2025 financials finalized in this filing?

How is the preliminary financial information for Atea Pharmaceuticals treated under securities laws?

What exhibits are included with this Atea Pharmaceuticals (AVIR) 8-K?

The related press release provides Atea Pharmaceuticals’ estimated preliminary cash and investment balance as of December 31, 2025, based on information available at the time.

Atea Pharmaceuticals, Inc. filed a current report to disclose that it issued a press release with its preliminary unaudited cash and investment balance as of December 31, 2025.

Accepted by SEC EDGAR 01/08/2026 - 09:05 AM EST

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Atea Pharmaceuticals, Inc. filed a current report to disclose that it issued a press release with its preliminary unaudited cash and investment balance as of December 31, 2025. The details of this estimated balance are contained in the press release furnished as Exhibit 99.1.

The company emphasizes that this financial information is preliminary, based on currently available data, and remains subject to completion of its fourth-quarter and full-year 2025 financial closing and audit procedures. The information has not been audited or reviewed by its independent registered public accounting firm and is furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Atea Pharmaceuticals disclosed that it issued a press release containing its preliminary unaudited cash and investment balance as of December 31, 2025, furnished as Exhibit 99.1.

No. The company states that the preliminary financial information as of December 31, 2025 has not been audited or reviewed by its independent registered public accounting firm.

No. The company notes that its financial closing procedures for the fourth quarter and full year 2025 are not yet complete, so actual results may differ from the preliminary data.

The company specifies that the information in Item 2.02, including Exhibit 99.1, is furnished and not filed, so it is not subject to Section 18 liability of the Exchange Act or automatically incorporated into other filings.

ATEA PHARMACEUTICALS, INC.

Date: January 8, 2026

/s/ Andrea Corcoran

Andrea Corcoran

Chief Financial Officer and Executive Vice President, Legal
and Secretary

The filing includes Exhibit 99.1, a press release dated January 8, 2026, and Exhibit 104, the cover page interactive data file with Inline XBRL tags.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 8, 2026

Atea Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39661

46-0574869

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer
Identification Number)

225 Summer Street

Suite 2100

Boston, MA 02110

(Address of principal executive offices) (Zip Code)

(857) 284-8891

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

AVIR

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 8, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing, among other things, the Company’s preliminary unaudited cash and investment balance as of December 31, 2025. The full text of the press release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such a filing.

Financial Disclosure Advisory

Exhibit 99.1 contains certain estimated preliminary financial information as of December 31, 2025, which is based on the information available to the Company at this time. The Company’s financial closing procedures for the fourth quarter and full year 2025 are not yet complete and, as a result, actual results may vary from the estimated preliminary information presented here due to the completion of the Company’s financial closing and audit procedures. The estimated preliminary financial information has not been audited or reviewed by the Company’s independent registered public accounting firm and should not be viewed as a substitute for the Company’s full interim or annual financial statements. Accordingly, you should not place undue reliance on this preliminary data.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.


Exhibit No.		Description

99.1		Press release dated January 8, 2026.

104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR